- Home
- MYGN vs CHCO Comparison
MYGN vs CHCO Comparison
Compare MYGN & CHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- CHCO
- Stock Information
- Founded
- MYGN 1991
- CHCO 1957
- Country
- MYGN United States
- CHCO United States
- Employees
- MYGN N/A
- CHCO N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CHCO Major Banks
- Sector
- MYGN Health Care
- CHCO Finance
- Exchange
- MYGN Nasdaq
- CHCO Nasdaq
- Market Cap
- MYGN 2.0B
- CHCO 1.9B
- IPO Year
- MYGN 1995
- CHCO N/A
- Fundamental
- Price
- MYGN $15.25
- CHCO $130.24
- Analyst Decision
- MYGN Buy
- CHCO Hold
- Analyst Count
- MYGN 12
- CHCO 4
- Target Price
- MYGN $27.64
- CHCO $112.25
- AVG Volume (30 Days)
- MYGN 990.7K
- CHCO 55.3K
- Earning Date
- MYGN 11-07-2024
- CHCO 10-24-2024
- Dividend Yield
- MYGN N/A
- CHCO 2.43%
- EPS Growth
- MYGN N/A
- CHCO N/A
- EPS
- MYGN N/A
- CHCO 7.80
- Revenue
- MYGN $823,600,000.00
- CHCO $289,546,000.00
- Revenue This Year
- MYGN $13.85
- CHCO N/A
- Revenue Next Year
- MYGN $7.73
- CHCO $0.25
- P/E Ratio
- MYGN N/A
- CHCO $16.70
- Revenue Growth
- MYGN 12.15
- CHCO 0.71
- 52 Week Low
- MYGN $15.18
- CHCO $95.39
- 52 Week High
- MYGN $29.30
- CHCO $136.51
- Technical
- Relative Strength Index (RSI)
- MYGN 16.18
- CHCO 61.65
- Support Level
- MYGN $16.86
- CHCO $114.82
- Resistance Level
- MYGN $19.60
- CHCO $136.00
- Average True Range (ATR)
- MYGN 1.17
- CHCO 3.30
- MACD
- MYGN -0.25
- CHCO 1.01
- Stochastic Oscillator
- MYGN 0.90
- CHCO 71.09
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About CHCO City Holding Company
City Holding Co is a financial holding company. It provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, saving accounts, credit card and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance, technology products, and others. These products and services are provided to commercial banking, consumer banking, mortgage banking, wealth management, and trust services.